PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

TB-500: Research & Evidence

Early-Stage Research

Published research, clinical trial data, and evidence grading for TB-500 across studied indications.

Back to TB-500 overview

Research Summary

TB-500 has strong preclinical data showing tissue repair and anti-inflammatory effects in multiple animal models, but human evidence is extremely limited with zero published RCTs specifically on TB-500. Most human study claims conflate this fragment with full thymosin beta-4.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Wound healing Tier C 8 Strong preclinical, limited human clinical data
Musculoskeletal recovery Tier C 5 Animal models show accelerated recovery
Cardiac repair Tier D 2 Promising preclinical, no human RCTs

Graded using our evidence tier methodology.

Citations (10 sources)

  1. 1. Germinal peptide eye drop promotes corneal epithelial and stromal defect healing in rabbit model. Study

    (2022), Seminars in ophthalmology

  2. 2. Thymosin β4 released from functionalized self-assembling peptide activates epicardium and enhances repair of infarcted myocardium. Clinical Trial

    (2021), Theranostics

  3. 3. Adjunctive Thymosin Beta-4 Treatment Influences PMN Effector Cell Function. Study

    (2021), Cells

  4. 4. Ethosomal Gel for Improving Transdermal Delivery of Thymosin β-4. Study

    (2019), International journal of nanomedicine

  5. 5. A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing. Study

    (2013), Drug design, development and therapy

  6. 6. Thymosin beta 4 ameliorates hyperglycemia and improves insulin resistance of KK Cg-Ay/J mouse. Study

    (2012), Diabetes research and clinical practice

  7. 7. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Clinical Trial

    (2010), Annals of the New York Academy of Sciences

  8. 8. The effect of thymosin treatment of venous ulcers. Study

    (2010), Annals of the New York Academy of Sciences

  9. 9. Effects of thymosin beta 4 and thymosin beta 10 on actin structures in living cells. Study

    (1994), Cell motility and the cytoskeleton

  10. 10. Thymosin beta 4 synergizes with human granulocyte-macrophage colony-stimulating factor in maintaining bone marrow proliferation. Study

    (1993), Immunopharmacology